Trading Statement Third Quarter 2007

Amsterdam, the Netherlands - Ahold today announced consolidated net sales of ¤6.3 billion for the third quarter ending October 7, 2007. Compared to the third quarter of 2006, net sales increased by 1.1% and increased by 5.6% at constant exchange rates. In the United States, price investments related to the further roll-out of the Value Improvement Program, launched in September 2006 at Stop & Shop and Giant-Landover, will continue to impact margins. At Giant-Carlisle, seasonally low sales will also be reflected in margins. In the Netherlands, market conditions remained favorable. Sales performance Stop & Shop / Giant-Landover * Net sales increased 0.3% to $3.7 billion. * Identical sales increased 1.2% at Stop & Shop (1.0% excluding gasoline net sales) and decreased 1.8% at Giant-Landover. * Comparable sales increased 1.7% at Stop & Shop and decreased 1.6% at Giant-Landover. Giant-Carlisle * Net sales increased 13.1% to $1 billion, due in part to the acquisition of the Clemens Markets stores in the fourth quarter of 2006. * Identical sales increased 2.5% (2.3% excluding gasoline net sales). * Comparable sales increased 3.7%. Albert Heijn * Net sales increased 12.4% to ¤1.8 billion, due in part to the acquisition of the Konmar stores in the fourth quarter of 2006. * Net sales at Albert Heijn supermarkets increased 12.5% to ¤1.6 billion. * Identical sales at Albert Heijn supermarkets increased 7.3%. Albert / Hypernova (Czech Republic and Slovakia) * Net sales increased 13.1% to ¤355 million (9.9% at constant exchange rates). * Identical sales increased 7.4%. Schuitema * Net sales increased 1.7% to ¤728 million. * Identical sales increased 0.4%. Unconsolidated joint venture - ICA * Net sales increased 21.1% to ¤2.2 billion, largely reflecting ICA's acquisition of the full ownership of Rimi Baltic AB from December 2006. At constant exchange rates, net sales increased 20.9%. Ahold Press Office: +31 (0)20 509 5343 Please open the link below for the full version of the Trading Statement Q3 2007: